REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

12/02/2021 16:30

RNS Number : 0050P
  
GlaxoSmithKline PLC
  
12 February 2021
  
 

                 
GlaxoSmithKline plc (the 'Company')
 
2021 Awards under the Deferred Investment Award Programme
Notional Award
 
On 10 February 2021, the Company granted awards over notional Ordinary Shares to Persons Discharging Managerial Responsibilities ('PDMRs') under the GlaxoSmithKline Deferred Investment Award programme. 
 
Under the programme, awards are made over notional Ordinary Shares with vesting phased over a specified period to provide long-term alignment with shareholders.  Vesting is subject to the PDMR not having served the Company notice or having been terminated by the Company for cause.  Dividends will accrue on the award during the vesting period through reinvestment in additional notional shares. On vesting, the award and accrued dividends will be paid in cash. Executive Directors are not eligible to receive awards under the programme.  
 
The awards have been made to support the retention of the PDMRs listed below.  The awards will vest 50% on 10 February 2024, 25% on 10 February 2025, and the balance on 10 February 2026.
 
The closing Ordinary Share price on 10 February 2021, used to determine the awards, was £12.75.     
 




 
 
Transaction notification
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Connor




b)


Position/status


President, Global Vaccines




c)


Initial notification/
amendment


Initial Notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
 
 
 
 
 
 
 




c)


Price(s) and 
volume(s)






Price(s)


Volume(s)












£12.75


78,431.373


























d)


Aggregated information


n/a (single transaction)




Aggregated volume Price








e)


Date of the transaction


2021-02-10




f)


Place of the transaction
 


n/a



 




 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr L Miels




b)


Position/status


President, Global Pharmaceuticals




c)


Initial notification/
amendment


Initial Notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
 
 
 
 
 
 
 




c)


Price(s) and 
volume(s)






Price(s)


Volume(s)












£12.75


78,431.373


























d)


Aggregated information


n/a (single transaction)




Aggregated volume Price








e)


Date of the transaction


2021-02-10




f)


Place of the transaction
 


n/a







 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Simard




b)


Position/status


President, Pharmaceuticals Supply Chain




c)


Initial notification/
amendment


Initial Notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
 
 
 
 
 
 
 




c)


Price(s) and 
volume(s)






Price(s)


Volume(s)












£12.75


39,215.686


























d)


Aggregated information


n/a (single transaction)




Aggregated volume Price








e)


Date of the transaction


2021-02-10




f)


Place of the transaction
 


n/a



 




 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Waterhouse




b)


Position/status


CEO of ViiV Healthcare




c)


Initial notification/
amendment


Initial Notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
 




b)


Nature of the transaction


A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
 
 
 
 
 
 
 




c)


Price(s) and 
volume(s)






Price(s)


Volume(s)












£12.75


78,431.373


























d)


Aggregated information


n/a (single transaction)




Aggregated volume Price








e)


Date of the transaction


2021-02-10




f)


Place of the transaction
 


n/a



 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHQLLFFFLLLBBZ